跳至主要内容
临床试验/NCT00421005
NCT00421005Unknown4 期

Safety and Efficacy of Fluvastatin in Heart Transplant Recipients

University of Bologna1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2004年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
56
试验地点
1

研究概览

简要总结

Statin therapy is a treatment with a proven positive impact on survival after heart transplantation. However, it is unclear whether the beneficial effect of this class of drugs depends solely on their LDL-lowering properties or on anti-inflammatory and immuno-modulatory properties. Thus, this study was designed to compare safety and efficacy of two different strategies: 1. high fixed statin dose vs. 2. low starting dose with LDL-driven doses adjustments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • De novo heart transplantation

排除标准

  • Known allergy/intolerance to fluvastatin;
  • Preexisting neuromuscular disorders;
  • Significant liver disease and/or elevation of transaminase exceeding 3 times the ULN
  • Severe renal impairment : creatinine > 3 mg/dL
  • Intellectual/cognitive impairment likely to compromise informed consent or adherence to protocol or age <18 years.
  • Patients refusal
  • Pregnancy

研究组 & 干预措施

1

Experimental

Fluvastatin 80mg

干预措施: fluvastatin (Drug)

2

Active Comparator

Fluvastatin 20, tapered up according to LDL concentration

干预措施: fluvastatin (Drug)

研究者

发起方
University of Bologna
申办方类型
Other

研究点 (1)

Loading locations...

相似试验